Pirtobrutinib,Venetoclax,Rituximab
Eli Lilly,Roche,Abbvie
['leusm', 'lymsm', 'valent ,(-prevalent)', 'loxo', 'valent ,(-prevalent),(-equivalent),(-bivalent)']
poster presentation at #eha2023 a comparison of bleeding-related events in patients who received a highly selective, non-covalent (reversible) btk inhibitor with and without antithrombotic agents. #lymsm #leusm see the results here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK